Evidence map›Paper›PMID 41852881›Full record

ArticleMaterials today. Bio2026

Bioresponsive PDA-GelMA hydrogel microspheres coordinate redox-immune homeostasis via controlled rhMUC13 delivery for radiation-induced intestinal injury.

Zhi Ling, Jinqiang Zhuang, Mingyan Wang, Xi Lin, Yefei Zhu, Xinyi Liu, Zifan Ding, Qingxie Liu, Weijuan Gong, Guotao Lu and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Zhi LingDepartment of Oncology, Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, China.
Jinqiang ZhuangYangzhou Key Laboratory for Precision Therapy of Refractory Bowel Diseases, Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, China.
Mingyan WangSchool of Medicine, Jiangsu University, Zhenjiang, China.
Xi LinDepartment of Gastroenterology, National Clinical Research Center for Digestive Diseases, Changhai Hospital, Naval Medical University, Shanghai, China.
Yefei ZhuYangzhou Key Laboratory for Precision Therapy of Refractory Bowel Diseases, Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, China.
Xinyi LiuYangzhou Key Laboratory for Precision Therapy of Refractory Bowel Diseases, Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, China.
Zifan DingCollege of Physical Education, Yangzhou University, Yangzhou, China.
Qingxie LiuYangzhou Key Laboratory for Precision Therapy of Refractory Bowel Diseases, Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, China.
Weijuan GongYangzhou Key Laboratory for Precision Therapy of Refractory Bowel Diseases, Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, China.
Guotao LuYangzhou Key Laboratory for Precision Therapy of Refractory Bowel Diseases, Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, China.
Xudong YinDepartment of Oncology, Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, China.
Yunfeng SunDonghai County People's Hospital, Lianyungang Clinical Medical College of Yangzhou University, Yangzhou University, Lianyungang, China.
Zhihao WangYangzhou Key Laboratory for Precision Therapy of Refractory Bowel Diseases, Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, China.
Yaodong WangDepartment of Gastroenterology, Kunshan Hospital of Traditional Chinese Medicine, Suzhou Key Laboratory of Integrated Traditional Chinese and Western Medicine of Digestive Diseases, Kunshan Affiliated Hospital of Yangzhou University, Yangzhou University, Kunshan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radiation-induced intestinal injury (RIII) remains a major clinical challenge, partly due to the lack of local delivery systems capable of concurrently coordinating oxidative stress and immune responses at the lesion site. In this study, we identify the transmembrane mucin MUC13 as a key regulator of intestinal epithelial homeostasis. MUC13 deficiency aggravates oxidative stress, epithelial apoptosis, and inflammatory responses, whereas supplementation with recombinant human MUC13 (rhMUC13) markedly attenuates epithelial injury. To achieve site-specific and durable delivery to inflamed tissue, we developed an inflammation-responsive polydopamine-gelatin methacryloyl (PDA-GelMA) hydrogel microsphere system that integrates targeted local delivery with intrinsic microenvironment modulation. The therapeutic efficacy arises from complementary, component-specific functions. The PDA shell mediates inflammation-associated adhesion and prolonged mucosal retention, rapidly scavenges reactive oxygen species (ROS), suppresses early inflammatory amplification, and promotes macrophage polarization toward a reparative M2 phenotype. Within this favorable redox-immune milieu, the GelMA core enables sustained rhMUC13 release, enhancing epithelial survival and barrier reconstruction by inhibiting NF-κB-associated pro-apoptotic signaling (the Bax/Bcl-2 axis) and restoring tight-junction proteins (ZO-1, Occludin, and Claudin-1). This cooperative mechanism likely accounts for the superior efficacy of the composite microspheres compared with single-component controls. Moreover, 16S rRNA gene sequencing revealed that irradiation induces pronounced gut microbiota dysbiosis, characterized by disrupted microbial diversity and community structure, increased inflammation-associated opportunistic taxa, and reduced beneficial commensal/metabolism-related bacteria; notably, PDA-GelMA@rhMUC13 partially ameliorated irradiation-induced dysbiosis, showing an overall remodeling trend toward reduced inflammation-associated taxa and increased putatively beneficial and metabolism-related bacteria. Collectively, these findings establish MUC13 as a critical mediator of epithelial-immune crosstalk and introduce a multifunctional hydrogel microsphere platform that combines targeted protein delivery with endogenous antioxidative and immunomodulatory capacities. This strategy may additionally promote restoration of intestinal homeostasis through microbiota remodeling, offering translational potential for RIII and other inflammatory intestinal disorders.

Indexed as

GelMA hydrogel microspheresInflammation-targeted therapyMacrophage polarizationMUC13PolydopamineRadiation-induced intestinal injurySustained protein delivery

Identifiers

PMID41852881
PMCPMC12993424

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.